Niagen Bioscience (NAGE) Insider Gary Buys 31,746 Shares

Ng Wang Yu Gary Leads Massive Insider Buy Order

Ng Wang Yu Gary acquired 31,746 shares of Niagen Bioscience, Inc. (NASDAQ: NAGE) on June 24, 2026. This transaction was part of a highly coordinated wave of insider buying, with six different company insiders purchasing the exact same amount of stock on the very same day. These transactions were reported to the SEC in standard insider disclosures.

The simultaneous purchases represent a notable vote of confidence in the bioscience firm. While the share price and total transaction values were listed as zero in the filings—often signifying equity grants, award vests, or structured compensation rather than open-market purchases—the uniform timing and sizing across six different individuals stand out as an unusually large block of insider accumulation.

Broad Insider Participation at Niagen Bioscience

This was not an isolated transaction. On June 24, 2026, five other insiders executed identical transactions to acquire 31,746 shares each. The participating individuals included Yu Wing Tak Wendy, Hamed Shahbazi, Steven Rubin, Kristin Patrick, and Ann Cohen. None of these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, meaning they were executed directly on that date.

Such a sweeping, identical block of transactions suggests a structured compensation event or a coordinated board-level action rather than independent market timing by individual executives.

Niagen Bioscience Stock Performance

Shares of Niagen Bioscience traded at $3.42 on Saturday. The stock has been trading in a wide 52-week range, from a low of $2.87 to a high of $10.52.

At its current price, the stock is sitting just above its 50-day moving average of $3.18, but it remains well below its 200-day moving average of $4.47. The company's total market value sits at approximately $240.5 million.

Recent Earnings

Niagen Bioscience reported annual revenue of $129.08 million, though it experienced a slight revenue decline of 4.3% compared to the prior period. The company remains profitable, showing a net margin of 12.39% and a return on equity of 21.8%.

Its trailing P/E ratio is 16.0, which rises to a forward P/E of 30.4 based on future earnings projections. Investors looking ahead can mark November 3, 2026, on their calendars, which is when the company is scheduled to release its next quarterly earnings report.

Healthy Aging and Dietary Supplements

Niagen Bioscience develops and sells healthy aging products and dietary supplements. Formerly known as ChromaDex Corporation, the company rebranded in early 2025 to focus heavily on its flagship ingredient, Niagen, which supports cellular metabolism. They sell directly to consumers online and supply raw materials to other health product manufacturers.

What to Watch

With multiple board members and insiders accumulating shares on the exact same day, market observers will be watching to see if this precedes any major product announcements or strategic shifts. Investors should monitor upcoming ownership filings to see if this coordinated accumulation continues as the next earnings date approaches.